Edition:
United States

Cardiome Pharma Corp (CRME.OQ)

CRME.OQ on NASDAQ Stock Exchange Capital Market

1.49USD
15 Dec 2017
Change (% chg)

$0.06 (+4.20%)
Prev Close
$1.43
Open
$1.43
Day's High
$1.50
Day's Low
$1.43
Volume
11,600
Avg. Vol
29,162
52-wk High
$4.83
52-wk Low
$1.29

Summary

Name Age Since Current Position

W. James O'Shea

2015 Independent Chairman of the Board

William Hunter

52 2013 President, Chief Executive Officer, Director

Justin Renz

45 2017 Chief Financial Officer

Sheila Grant

2013 Chief Operating Officer

David McMasters

2012 Corporate General Counsel

David Dean

2017 Chief Business Development Officer

Jennifer Archibald

2017 Chief Business Operations Officer

Hugues Sachot

2017 Chief Commercial Officer

Richard Glickman

57 2007 Lead Independent Director

Mark Corrigan

60 2015 Independent Director

Robert Meyer

2015 Independent Director

Arthur Willms

74 2015 Independent Director

Biographies

Name Description

W. James O'Shea

Mr. W. James O'Shea serves as an Independent Chairman of the Board of the Company. Mr. O’Shea was President and Chief Operating Officer of Sepracor Inc., or Sepracor, from October 1999 to March 2007 where he was responsible for successfully building that organization’s commercial infrastructure. From April to August 2007, Mr. O’Shea served as Sepracor’s Vice Chairman. Prior to Sepracor, Mr. O’Shea was Senior Vice President of Sales and Marketing and Medical Affairs for Zeneca Pharmaceuticals, a business unit of Astra Zeneca Plc, a publicly held biopharmaceutical company. Mr. O’Shea is past Chairman of the National Pharmaceutical Council and is also a board member of BTG Plc, Prostrakan Group Plc, Ocular Therapeutics and Trevi Therapeutics. Mr. O’Shea has served on the audit committees of other publicly listed companies.

William Hunter

Dr. William L. Hunter, M.D., serves as President, Chief Executive Officer, Director of Cardiome Pharma Corp. Dr. Hunter has been a member of Cardiome's Board of Directors since 2007 and became the Company's President and CEO in July 2012. Prior to Cardiome, Dr. Hunter co-founded Angiotech in 1992 and assumed the position of Chief Executive Officer in 1997 when Angiotech was a venture-stage, private, pre-clinical company with less than 50 employees. He led Angiotech through three rounds of private equity financing, the Company’s IPO and listing on the TSX and the NASDAQ, over $1 billion in equity and debt financings, a debt restructuring and eight separate corporate acquisitions. During that time, Angiotech grew to become a profitable, diversified, healthcare company with over 1,400 employees, several thousand commercially available products, 12 facilities in five countries and worldwide annual revenues exceeding $250 million. Dr. Hunter has over 200 patents and patent applications to his name and products in which he was an inventor or co-inventor include the TAXUS® Drug-Eluting Coronary Stent, the Zilver PTX Peripheral Drug-Eluting Stent, the Quill barbed wound closure device and the 5-FU Anti-Infective Catheter; combined these products have been used in over 6 million patients and recorded revenues of over $12 billion worldwide. Dr. Hunter currently serves as a director of Epirus Pharmaceuticals Inc. (NASDAQ: EPRS) and Rex Bionics Plc, and selected awards he has received include the 2006 Principal Award from the Manning Foundation (one of Canada’s highest awards for innovation); BC Innovation Council’s Cecil Green Award for Science and Technology Entrepreneurship; Entrepreneur of the Year from the Canadian Venture Capital and Private Equity Association; and Canada’s 40 Under 40. Dr. Hunter served as a practicing physician in British Columbia for five years.

Justin Renz

Mr. Justin A. Renz is Chief Financial Officer of the Company. He has extensive experience in the biopharmaceutical industry. He most recently served as executive vice-president, chief financial officer and treasurer at Karyopharm Therapeutics, which he joined in August, 2014, where he led core business and finance functions. Prior to Karyopharm, Mr. Renz was executive vice-president, chief financial officer and treasurer at Zalicus Inc. (formerly CombinatoRx Inc.), which he joined in September, 2006. He oversaw multiple rounds of equity and debt financing and led the company's asset monetization strategy and two reverse mergers. Prior to Zalicus, Mr. Renz served in senior finance and accounting roles at Serono Inc. and Coley Pharmaceutical Group Inc.

Sheila Grant

Ms. Sheila M. Grant, MBA,, serves as Chief Operating Officer of Cardiome Pharma Corp. since March 26, 2013. Ms. Grant is Cardiome's Chief Operating Officer. Ms. Grant was most recently Cardiome’s Vice President of Product Development, with responsibility for the overall management of the vernakalant (IV) program. She has overseen the development of vernakalant from its initial preclinical studies through to commercialization. Ms. Grant’s past roles at Cardiome have included Vice President, Commercial Affairs and Director of Business & Clinical Development. Prior to joining Cardiome, Ms. Grant acted as business consultant to De Novo Enzyme Corporation and Coopers & Lybrand. Ms. Grant also worked in research and development, production, and quality assurance with Schering Agrochemicals U.K., Wellcome Biotechnologies U.K. and Serono Diagnostics U.K.. Ms. Grant holds an MBA degree from Simon Fraser University.

David McMasters

Mr. David D. McMasters, J.D., serves as Corporate General Council of the Company. Mr. McMasters is Cardiome’s General Counsel, and oversees all legal affairs of the Company. Mr. McMasters was formerly General Counsel to Angiotech for 11 years, and, prior to that, was the Managing Partner of a mid-sized intellectual property law firm (Seed Law Group).

David Dean

Mr. David C. Dean is Chief Business Development Officer of the Company. Mr. Dean has 15 years of capital markets experience as a top ranked industry analyst focused exclusively on the Canadian healthcare sector, most recently as a Director and Research Analyst at one of Canada’s leading independent investment banks. Mr. Dean attained a M.Sc. from the University of Ottawa with a focus on Cardiac Physiology as well as an MBA (Finance) from Queens University.

Jennifer Archibald

Ms. Jennifer Archibald, CPA, CA, is Chief Business Operations Officer of Cardiome Pharma Corp. Ms. Archibald is Cardiome’s Chief Financial Officer, with responsibility for overseeing Cardiome’s financial operations. She joined Cardiome in 2006 and served as Cardiome’s Director of Finance until her appointment as Chief Financial Officer in September 2012. Ms. Archibald has extensive accounting and finance experience, dealing with the complexities of both public and private corporations. Prior to joining Cardiome, Ms. Archibald managed the accounting operations at the corporate office of The Jim Pattison Group. Ms. Archibald began her career as a corporate auditor with KPMG LLP (“KPMG”) performing audit, tax and accounting work. She is a Chartered Accountant and earned a Bachelor of Commerce degree from the University of British Columbia.

Hugues Sachot

Mr. Hugues Sachot is Chief Commercial Officer of the Company. Mr. Sachot was appointed an Officer of the Corporation on June 22, 2015. Mr. Sachot is Cardiome’s Senior Vice President of Sales and leads the commercial organization in all direct market and distributor sales worldwide. He was previously Vice President of Commercial at Angiotech.

Richard Glickman

Dr. Richard M. Glickman, LL.D., serves as Lead Independent Director of Cardiome Pharma Corp. Dr. Glickman was a co-founder and Executive Chairman of Aurinia Pharmaceuticals, or Aurinia, and currently serves as the Chairman of the Board for Aurinia. Dr. Glickman was a co-founder, Chairman and Chief Executive Officer of Cardiome Pharma Corp. Prior to establishing Aspreva, Dr. Glickman was the co-founder and Chief Executive Officer of StressGen Biotechnologies Corporation. Since 2000, Dr. Glickman has served as the Chairman of the Board of Vigil Health Solutions Inc., a healthcare services company and more recently, as Chairman of the Board of Essa Pharmaceuticals Inc. Dr. Glickman was also the founder and a director of Ontario Molecular Diagnostics, a diagnostic facility that evolved into the largest molecular diagnostic laboratories in Canada. He co-founded Probtec Corporation, a rational drug design and molecular genetics firm, where he established and introduced the first licensed DNA-based forensic and paternity testing services in Canada. He has served on numerous biotechnology boards including roles as Chairman of Life Sciences B.C. (formerly the British Columbia Biotechnology Alliance), Director of the Canadian Genetic Disease Network and a member of the federal government’s National Biotechnology Advisory Committee. Dr. Glickman currently serves as a member of the British Columbia Innovation Council and a Director for the Vancouver Aquarium. Dr. Glickman received the Ernst & Young Entrepreneur of the Year 2004 Award for the Pacific Region Life Sciences Group and has received both Canada’s and British Columbia’s Top 40 under 40 Award for Entrepreneurs and has been the recipient of 2006 BC Biotech Leadership Award. Dr. Glickman has served on the audit committees of other publicly listed companies.

Mark Corrigan

Dr. Mark H. N. Corrigan. M.D., serves as an Independent Director of the Company. Dr. Corrigan was the Chairman of the Board of Directors at Epirus Biopharmaceuticals, Inc. until July 2016, and was a former Board member of Cubist Pharmaceuticals, Inc. He was formerly the Chief Executive Officer of Zalicus Inc., prior to its merger with Epirus Biopharmaceuticals Inc., and prior to that was the executive vice president of R&D at Sepracor Inc. Prior to Sepracor Inc., he spent 10 years with Pharmacia & Upjohn, where he served most recently as Group Vice President of Global Clinical Research and Experimental Medicine.

Robert Meyer

Dr. Robert James Meyer, M.D. serves as Independent Director of Cardiome Pharma Corp. Dr. Meyer is currently a Director at the Virginia Center for Translational and Regulatory Sciences at the University of Virginia School of Medicine, but has held senior roles at Merck Research Laboratories from 2007 to 2013, most recently as Vice President, Global Regulatory Strategy, Policy and Safety, as well as at the FDA from 1999 to 2007 where Dr. Meyer served as Director of the Division of Pulmonary and Allergy Drug Products and then Director of the Office of Drug Evaluation II in the Center for Drug Evaluation and Research.

Arthur Willms

Mr. Arthur H. Willms serves as Independent Director of the Company. Mr. Willms currently participates on several boards, including the Board of Directors of: Naikun Wind Energy Group Inc.; 2010 Games Operating Trust; Advanced Applied Physics Solutions; and Pacific Autism Family Centre Foundation. He was previously the President and Chief Operating Officer of Westcoast Energy Inc. Mr. Willms has a B.A. in Mathematics and an M.A. in Economics and has served on numerous audit committees of major corporation entities.

Basic Compensation

Name Fiscal Year Total

W. James O'Shea

195,721

William Hunter

2,002,890

Justin Renz

--

Sheila Grant

593,168

David McMasters

730,898

David Dean

--

Jennifer Archibald

628,168

Hugues Sachot

772,006

Richard Glickman

164,417

Mark Corrigan

193,771

Robert Meyer

152,099

Arthur Willms

97,971
As Of  30 Dec 2016